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Background: Patients with Chronic Obstructive Pulmonary Disease (COPD) are at higher risk of
developing Community-Acquired Pneumonia (CAP) than patients in the general population.
However, no studies have been performed in general practice assessing longitudinal incidence
rates for CAP in COPD patients or risk factors for pneumonia onset.
Methods: A cohort of COPD patients aged  45 years, was identified in the General Research
Practice Database (GPRD) between 1996 and 2005, and annual and 10-year incidence rates of
CAP evaluated. A nested case-control analysis was performed, comparing descriptors in COPD
patients with and without CAP using conditional logistic regression generating odds ratios (OR)
and 95% confidence intervals (CI).
Results: The COPD cohort consisted of 40,414 adults. During the observation period, 3149
patients (8%) experienced CAP, producing an incidence rate of 22.4 (95% CI 21.7e23.2) per
1000 person years. 92% of patients with pneumonia diagnosis had suffered only one episode.
Multivariate modelling of pneumonia descriptors in COPD indicate that age over 65 years
was significantly associated with increased risk of CAP. Other independent risk factors20 8990 2647.
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Epidemiology of pneumonia in COPD 1125Figure 1 Patient floassociated with CAP were co-morbidities including congestive heart failure (OR 1.4, 95% CI 1.2
e1.6), and dementia (OR 2.6, 95%CI 1.9e3.). Prior severe COPD exacerbations requiring hospi-
talization (OR 2.7, 95% CI 2.3e3.2) and severe COPD requiring home oxygen or nebulised
therapy (OR 1.4, 95% CI 1.1e1.6) were also significantly associated with risk of CAP.
Conclusion: COPD patients presenting in general practice with specific co-morbidities, severe
COPD, and age >65 years are at increased risk of CAP.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) has been associated
with risk of hospitalization and mortality in patients with
chronic obstructive pulmonary disease (COPD).1e4 COPD
patients with CAP have been shown to have worse clinical
outcomes compared to similarly aged CAP patients without
COPD in terms of CAP severity, intensive care admissions,
and mortality.5,6 This excessive CAP burden among COPD
patients contributes to the overwhelming hospital and
societal costs.7 Most studies assessing co-morbid COPD and
CAP have focused on hospitalized patients, with small
convenience samples, which were not representative of
national populations. Study designs were limited to preva-
lence assessment or short-term follow up.1,3,6
Observational and randomized clinical trials, reported an
increased risk of CAP in COPD patients exposed to inhaled
corticosteroids (ICS).8e16 These studies, however, did not
usually report additional risk factorsfor CAP, such as other
co-morbidities, clinical characteristics, and consulting
history. Accurate assessment of risk of CAP in COPD patients
will improve awareness of clinically relevant risk factors.
This should assist with timely diagnosis and treatment to
reduce the CAP burden within the COPD population Under-
standing factors which are both associated with and/orw diagram (CONSORT) - identipredict CAP incidence requires comparing COPD patients
with and without CAP in a large clinical population.
We performed a longitudinal evaluation of a represen-
tative sample of the UK general practice population to
assess the incidence, natural history, and risk factors for
CAP in a COPD population.Materials and methods
Study design and patient population
Data were obtained from the General Practice Research
Database (GPRD) for the observation period between
January 1st, 1996 and December 31st, 2005. The GPRD
contains complete data onmore than 5million patients from
England and Wales from several hundred general practices.
These data are representative of the age and gender struc-
ture in the UK general population17 and accurately reflect
clinical reported respiratory disease diagnosis.18
This study used a population-based retrospective cohort
design toestimate incidenceandnatural history ofCAPwithin
the prevalent COPD population. The cohort selection evolu-
tion is described in Fig. 1. COPDpatientswere defined as aged
45 years and over with a COPD diagnosis recorded in theirfication of study cohort and case ascertainment.
Table 1 Descriptive characteristics for the total COPD
cohort.
Variable Total cohort
N 40,414
Gender Male, % 51.7
Age in years (%) 45 to 64 37.1
65 to 79 49.9
80 and older 13.3
Smoking history (%) Current 39.9
Former 29.0
Non-Smoker 20.0
Unknown/Missing 11.1
COPD severity (%)a Mild 7.6
Moderate 75.2
Severe 17.1
Asthma history (%)b Yes 17.8
Prior pneumonia (%)c Yes 4.8
Patients with 1 CAP
episode within the
observation period (n, %)
1 (episode) 2887 (7.1)
2 (episodes) 228 (0.6)
3 (episodes) 28 (0.07)
4 (episodes) 5 (0.01)
5 (episodes) 1 (0.003)
a Mild patients Z not treated during observation, moderate
patients Z regular COPD treatment (2 prescriptions of the
same drug group within six months), severe patients Z oxygen
or nebulised therapy prescriptions.
b Asthma history refers to at least one asthma diagnosis prior
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and who had a subsequent COPD related prescription (i.e.
bronchodilators, inhaled or oral corticosteroids)within 1 year
from the first medical COPD diagnosis. Additionally, patients
had at least 24 months of total history in the GPRD, with 12
months of this history after the COPD diagnosis date to allow
reasonable time for assessment of the natural history of the
disease. Patients were excluded if they had a medical code
indicating a serious lung disease jthat would have interfered
with COPD outcomes. Patients were required to have
a minimum of one record of any diagnosis or medication per
year for any cause. Other censoring events included death,
transferring out of the practice, and end of follow up.
We implemented a nested case control design to compare
differences in clinical characteristics and medication expo-
sure from time of first COPD diagnosis in patients by subse-
quent CAP status. Patients were matched using a 1:5case to
control ratio on length of followup.Matching by timeensured
that patients had a similar length of history for covariate
collection and a similar probability of CAP diagnosis.
Outcome definition
The primary outcome was aphysician-recorded diagnosis of
CAP identified using a set of “Read” codes (diagnosis coding
system used by the GPRD). A single episode of CAP was
defined as taking up to 10 weeks to resolve; a minimum of 14
days without antibiotics or relevant health-care visits sepa-
rated one episode from another. See Appendix A regarding
criteria for longitudinal CAP events.
Covariates
Age,bodymass index (BMI) andsmoking statusweredefinedat
the first CAP episode and were based on the most recent
measurement prior to the this episode. Further, COPD treat-
ment history, vaccination related to pneumonia (pneumo-
coccaland influenza),numberofGPvisits, numberof referrals
to a pulmonologist, COPD exacerbations (see Appendix B for
definition), and respiratory medications and treatments
previously suggested to be associated with CAP incidence in
the literature (i.e. statins, ACE-inhibitors and immunosup-
pressive treatment including antiretroviralmedications)were
counted within 12 months prior to the first CAP episode19e21.
Co-morbid conditions were defined based on diagnosis
codes recorded during the observation period until the first
CAP episode. All diseases contained in the modified Charlson
co-morbidity index, in addition to depression, anxiety and
asthmawere included.22 COPD severitywas definedaccording
toprior published literature23 since lung function datawas not
yet recorded within the GPRD during the observation period.
Statistical analysis
Incidence and recurrence of CAP and all-cause mortality
were estimated for the observation period. Annual incidencej Cystic fibrosis, interstitial lung disease, pulmonary fibrosis, lung
agenesis, major lung surgery (transplantation, resection,
lobectomy).rates based on calendar timewere calculated by dividing the
number of patients with CAP diagnosed within a specific
year, by the total person-days of follow up within each
calendar year. Days were counted from January 1st until the
first date of the CAP episode. If no event occurred for
a patient, the day contribution was 365.25. If an event
crossed a calendar year, the event was included in the year
with the episode start date. Period incidence (10 year inci-
dence density, based on calendar time 1996e2005) was
calculated by dividing the number of community-acquired
pneumonia episodes by the total person-days of follow up.
Multiple events were included for all patients and person-
days ran from the end of one episode to the start of the next.
For both objectives, descriptive statistics were performed
and proportions were tested using the c2 test and continuous
variables using the Student’s t-test. Multivariate conditional
logistic regression modelling was used to assess risk factors
associated with CAP. Due to the large number of variables
only those significant at p < 0.05 in the group comparison
were included in the final model. Final estimates are
provided with 95% confidence limits. Analyses were con-
ducted using SAS version 9 (SAS Institute, Cary, NC).
Results
The COPD cohort consisted of 40,414 adults aged 45 years
and over. Cohorts characteristics are described in Table 1.
Men represented 52% of the cohort and approximately 40%to the start of the individual’s observation period (1st of
January 1996 or any later start date in GPRD).
c Prior pneumonia refers to an historical episode of
community-acquired pneumonia recorded prior to the start of
the individual’s observation period.
Table 2 The incidence rate of CAP episodes per 1000
person years of observation in a COPD cohort, 1996 to 2005,
stratified by covariates.
Stratum Value Rate 95%CI
Upper
95%CI
lower
Overall 22.4 21.7 23.2
Gender Female 21.4 20.4 22.5
Male 23.1 22.1 24.2
Age 45 to 64 11.3 10.3 12.3
65 to 79 19.8 18.9 20.8
 80 46.1 43.7 48.6
Smoking history Current 19.8 18.7 21.0
Former 21.4 20.2 22.8
Non-smoker 26.0 24.3 27.8
Unknown 28.7 25.9 31.9
Asthma historya Yes 26.1 24.4 27.9
No 21.2 20.4 22.1
Prior pneumoniab Yes 39.5 35.4 44.1
No 21.4 20.6 22.1
COPD severityc Mild 18.2 15.7 21.2
Moderate 19.2 18.4 20.0
Severe 35.9 33.8 38.1
a Asthma history refers to at least one asthma diagnosis prior
to the start of the individual’s observation period (1st of
January 1996 or any later start date in GPRD).
b Prior pneumonia refers to an historical episode of CAP
recorded prior to the start of the individual’s observation period
(1st of January 1996 or any later start date in GPRD).
c Mild patients Z not treated during observation period,
moderate patientsZ regular COPD treatment (2 prescriptions
of the same drug group within 6 months), severe patients
Z oxygen or nebulised therapy prescriptions (adapted from
Soriano et al.18).
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Figure 2 The 1-year incidence rates of community-acquired
pneumonia episodes (1996e2005) stratified by COPD severity.
Legend: mild patientsZ not treated during observation period,
moderate patientsZ regular COPD treatment (2 prescriptions
of the same drug group within six months), severe patients
Z oxygen or nebulised therapy prescriptions (adapted from
Soriano et al.18).
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Figure 3 The 1-year incidence rates of community-acquired
pneumonia episodes (1996e2005) stratified by influenza
vaccination status in the 12 months prior to the first CAP
episode.
Epidemiology of pneumonia in COPD 1127of patients were current smokers. A total of 3149 COPD
patients had suffered at least one CAP episode during the
observation period (8%). Of those that experienced CAP,
the majority (92%) had only one episode during 10-years of
observation. Between 1996 and 2005, 10,390 (25.1%) COPD
patients died in the cohort; overall 20% (n Z 2068) had
suffered CAP during the observation period. When splitting
COPD patients by their event of CAP, sixty percent of those
with CAP episode during the observation period died as
compared to 22% of those without a CAP episode.
The 10-year incidence rates for the observation period
are shown in Table 2. The incidence of CAP was most
strongly associated with age 80þ, history of asthma, history
of pneumonia, and COPD severity. The 1 year incidence of
CAP was highest in severe COPD patients showing fluctua-
tion in rate over time, with a stable rate for mild and
moderate patients, as illustrated in Fig. 2. Use of influenza
vaccine appears protective; rates of CAP in unvaccinated
patients were significantly higher than in vaccinated
patients for some years of follow up, [Fig. 3].
In the case control analysis, a total of 1469 COPD patients
with at least one diagnosed CAP episode between 1996 and
2005werematched on length of time in the database to 7345
COPD patients without CAP. COPD patients with CAP consis-
tently showed evidence of a more severe disease, with more
co-morbidities, and higher frequency of moderate and
severe COPD exacerbation (Table 3). Those with CAP weremore frequent users of ACE-inhibitors, were older, and had
higher utilization of GP care. Influenza vaccine rates were
high in both groups. Prevalence of COPD medications were
similar in terms of any ICS use, but the COPDpatientwith CAP
group had higher use of LABA.
Table 3 Characteristics of the COPD patients with at least one CAP episode during the observation period matched to patients
without a CAP diagnosis during their GPRD history.
Variable CAP diagnosis present CAP diagnosis absent p-value
n Z 1469 n Z 7345
Gender (male, %) 52.3 52.3 N.S.
Age in years, mean (SD) 75.1 (10.6) 70.9 (10.8) <0.001
Age, years (%) <0.001
45e64 18.0 28.4
65e79 44.9 48.4 <0.001
80 and older 37.0 23.3
Smoking history (%) 0.03
Current 36.7 41.1
Former 35.8 35.4
Non-smoker 20.4 17.5
Unknown/missing 7.1 6.0
Vaccination (%)
Influenza in the last 12 months 73.9 70.2 0.004
Pneumococcal in the last 5 years 39.7 37.1 0.07
BMI mean (SD) 25 (5.8) 26 (5.7) N.S.
COPD severity (%)a 0.001
Mild 19.7 23.1
Moderate 63.2 67.1
Severe 17.1 9.8
Comorbid conditions (%)
Asthma 45.4 43.9 N.S.
Myocardial infarction 12.0 9.5 0.005
Congestive heart failure 27.5 16.3 <0.001
Cerebrovascular disease 15.1 10.9 <0.001
Dementia 3.6 1.0 <0.001
Peptic ulcer 18.4 14.6 <0.001
Peripheral vascular disease 8.2 5.7 <0.001
Connective tissue disorder 45.8 38.2 <0.001
Diabetes 10.4 8.5 0.02
Anxiety 25.7 21.4 <0.001
Depression 29.2 24.4 <0.001
Lung cancer 2.0 1.6 N.S.
Renal diseases 4.1 2.2 <0.001
COPD therapyb (%)
Inhaled corticosteroids (ICS) containing products 63.6 61.9 N.S.
Long-acting beta2-agonists (LABA) 32.2 27.5 <0.001
Short-acting bronchodilators 83.9 86.1 0.03
Oral corticosteroids 43.2 33.3 <0.001
Home oxygen therapy 8.5 4.5 <0.001
Nebulised therapy 18.6 10.3 <0.001
Other medicinesb (%)
ACE-inhibitors 25.3 22.1 0.008
Statins 17.1 14.4 N.S.
Proton pump inhibitors 24.5 19.8 <0.001
Histamine H2 receptor blockers 11.2 9.5 0.045
COPD exacerbations (%)b
Severe exacerbation with hospitalization 17.1 5.5 <0.001
Moderate exacerbationc 14.0 7.9 <0.001
GP visitsb, mean (SD) 32.5 (18.7) 26.4 (16.4) <0.001
a Mild patients Z not treated, moderate patients Z regular COPD treatment (2 prescriptions of the same drug group within 6
months), severe patients Z oxygen or nebulised therapy prescriptions (adapted from Soriano et al.18).
b Descriptor measured in the 12 months prior to the first CAP episode.
c Moderate exacerbations were defined as: (1) treatment with oral steroids and antibiotics within 14 days time interval; (2) COPD
exacerbation diagnosis, or (3) acute bronchitis diagnosis.
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Epidemiology of pneumonia in COPD 1129Risk estimates for CAP diagnosis in primary care based on
multivariate regressionmodelling are shown inTable 4. COPD
patients age 65e79 and age 80 and older had increasingly
higher risk of CAP than younger patients. Higher BMI appears
protective against CAP compared to normal weight. Current
smoking status was not associated with CAP incidence.
Severe COPD was associated with an increased risk of CAP,
but risk amongmoderateCOPDwasnot significantly different
from mild COPD. Some co-morbid conditions were signifi-
cantly associated with of CAP, namely congestive heart
failure (OR 1.4 95% CI 1.2; 1.6), dementia (OR 2.6 95% CI 1.9;
3.8), peptic ulcer (OR1.2 95%CI 1.1; 1.4), peripheral vascular
disease (OR 1.3 95% CI 1.1; 1.6) and connective tissue disease
(OR 1.2 95% CI 1.0; 1.3). Prior hospitalizations for COPD
exacerbation and moderate COPD exacerbation were alsoTable 4 Factors associated with CAP occurrence, odds ratios an
logistic regression.
Variable O
Age category
Age 45e65 R
Age 65e80 1
Age 80 or over 1
BMI
<18.5 1
18.5e24.9 R
25.0e29.9 0
30 0
Smoking
Non-smoker R
Former 1
Current 0
COPD severitya
Mild R
Moderate 0
Severe 1
Influenza vaccination in prior 12 mo 0
Comorbid conditions prior to episode
Myocardial infarction 1
Congestive heart failure 1
Cerebrovascular disease 1
Dementia 2
Peptic ulcer 1
Peripheral vascular disease 1
Connective tissue disease 1
Diabetes 1
Anxiety 1
Depression 1
COPD hospitalisation (Severe exacerbation) 2
Moderate COPD exacerbationb 1
Number of GP visits in prior 12 moc
Very low: 1e14 R
Low: 15e22 1
Medium: 23e33 1
High: 34 1
a Mild patients Z not treated, moderate patients Z regular COPD
months), severe patients Z oxygen or nebulised therapy prescription
b Moderate exacerbations were defined as: (1) treatment with oral
exacerbation diagnosis, or (3) acute bronchitis diagnosis.
c All patients were required to have at least one visit to a GP in 12significantly associatedwith CAP, aswas the highest category
of GP visit frequency in the prior year(>15 visits).
Death occurred in 869 patients with CAP (59%) and in 2974
(41%) patients without CAP (Odds Ratio 2.1; 95% CI 2.2e2.7).
The average time to death was comparable between cases
and controls (372 days vs. 345 days, respectively).Discussion
The study results present the first evaluation of pneumonia
incidence, longitudinal patterns and risk factors as recor-
ded in UK general practice. Compared to other studies
conducted in the UK general practice, which considered all
adult patients registered in primary care, the risk of CAP ind 95% confidence intervals (CI), from multivariate conditional
dds ratio 95% CI
eference
.28 1.1 1.48
.86 1.57 2.22
.15 0.92 1.43
eference
.78 0.67 0.90
.71 0.60 0.85
eference
.04 0.90 1.2
.99 0.86 1.14
eference
.97 0.85 1.12
.35 1.11 1.63
.95 0.84 1.08
.00 0.85 1.19
.37 1.20 1.57
.08 0.93 1.26
.64 1.86 3.75
.22 1.06 1.41
.27 1.05 1.55
.16 1.04 1.30
.07 0.89 1.28
.09 0.95 1.25
.13 0.99 1.28
.73 2.32 3.20
.28 1.13 1.46
eference
.26 1.04 1.52
.31 1.08 1.58
.53 1.26 1.86
treatment (2 þ prescriptions of the same drug group within 6
s (adapted from Soriano et al.18).
steroids plus antibiotics within 14 days time interval; (2) COPD
mo prior to the event.
1130 H. Mu¨llerova et al.COPD is almost 10-fold higher.24,25 Further, this study
showed that 8% (3149) of the COPD cohort (40,414) suffered
an occurrence of one or more CAP episodes during 10-years
of follow up. 92% of these patients had only one episode
equating to an incidence rate of 22.4 per 1000 person years.
Significant risk factors associated with CAP included older
age, COPD severity, history of CAP episodes prior to start of
the observation period, and certain co-morbid conditions
including congestive heart failure, reflux disease and
dementia.
Several methodological issues could have affected the
results of this study. First, we were unable to validate the
CAP diagnosis listed in the patient record by chest radio-
graph since these data were from a large retrospective
cohort. Previous studies have shown that written clinical
diagnosis in the GPRD is accurate in terms of the physician’s
assessment of the disease state, and GPRD diagnosis rates
for pneumonia were similar to the 4th Morbidity Survey in
General Practice consultation rates.20,26 However, the
sensitivity and specificity of clinical variables are presum-
ably low, and therefore establishing the CAP diagnosis on
clinical observations alone may not be fully reliable.
Second, we defined a CAP episode length by expert clinical
knowledge, due to limited information in the published
data.27 Lastly, we matched patients with CAP to those
without CAP based on time spent in the database. Matching
on other criteria, such as age or gender, would have limited
our ability to statistically analyze the differences in these
covariates between groups.
A third potential limitation of this study design relates to
our definition of COPD. Because of the low incidence of
CAP, we intentionally selected a longer period of 10-years
to observe any trends over time and to collect a sufficient
number of events to enable a robust multivariate analysis
to characterizefactors associated with CAP. A programme
incentivising administration and collection of COPD indices
in the English primary (Quality Outcomes Framework) did
not come into practice until April 1, 2004. There are two
factors supporting the use of medical diagnosis only based
COPD ascertainment: (1) the codes used in this study were
derived based on the validation study by Soriano and
colleagues18 and (2) an almost identical list of medical
diagnoses has been used elsewhere in studies of COPD in
the UK primary care.28
Further, we observed about 20% of COPD patients in
GPRD labelled as non-smokers. This findings is in agreement
with the prevalence of non-smoking among COPD patients
as reported by Schneider and colleagues (22%).29It is also
consistent with the findings of population-based studies of
airway obstruction, namely the BOLD study.30 But, we can
never be confident the patients we describe as non-smokers
are true never smokers. Indeed, the small numerical
increase in the frequency of CAP in the non-smoker group
may indicate a possibility that some patients were in an
advanced stage of COPD and recently changed their
smoking, which may not be fully recorded.
The large size of the COPD population allowed for
increased precision of CAP incidence rates. The 10-year CAP
incidence rate in this study was 22.4 per 1000 person years. A
randomized clinical trial by Merino-Sanchez et al31 reported
a rate of 55.1 per 1000 personyears during 3 years of followup
in Spain; however, these subjects were more likely to havemore severe COPD than our general practice cohort. In the 3
year TORCH study, pneumonia incidence rate varied by
treatment arm from 30 to 55 events per 1000 treatment-
years; however, again this population differed substantially
from COPD patients managed in the community.12
Our results are supported by other reports of CAP being
associated with older age, lower BMI, and deteriorated lung
function, which correlates to the proxy severity categories
of oxygen and nebulised therapy use in our GPRD study.12,32
General risk factors for CAP, identified in previous studies,
mainly during a hospitalization for CAP, include age 65þ,
former or current smoking, male sex, and co-morbidities
such as chronic heart failure, advanced chronic obstruc-
tive pulmonary disease, neurological diseases, and liver
cirrhosis33e36. Age may show a positive association with
disease incidence because practitioners may more readily
diagnose pneumonia in an older patient, where prevalence
is known to be higher. In our study, current smoking was not
associated with CAP, while never and unknown smoking
status were associated with CAP in a univariate relation-
ship. No association with smoking was observed in a multi-
variate model. These associations could be due to
inaccurate recording of current smoking status, severe
COPD caused by occupational exposures or alpha1-
antitrypsin deficiency. Further, confounding by disease
severity may impact this observation, where COPD patients
with more severe disease tend to become former smokers
following smoking cessation. A ‘paradoxical’ lack of an
association of CAP occurrence with obesity has been
observed elsewhere.12,37 We can only speculate that this
observation can be a result of an increased readiness of GPs
to diagnose CAP in underweight patients. We did not
replicate an earlier finding of an association of diabetes
mellitus with an increased risk of CAP.32 This observation
can be explained as due to selection of a different pop-
ulation (the earlier study employed hospitalized pneumonia
definition only), potential misdiagnosis of diabetes in
primary care, or correlation of several diagnoses occurring
in the same patients such that any diabetes effect would be
mostly explained by other co-diagnoses.
During the 10-year observation period, 8% of patients
had one or more episodes of CAP, which probably indicates
impaired host defence in a minority of patients with COPD.
This occurrence is similar to previously reported incidence
of 9% for recurrent (CAP) requiring hospitalization.38
Overall, the majority of COPD patients were at low risk of
opportunistic infection. Congestive heart failure (CHF),
peripheral vascular disease, connective tissue disease,
peptic ulcer and dementia were significantly associated
with CAP incidence. CHF failure is commonly found in
hospitalized COPD patients with and without CAP2,5,39 and
is a predictor of mortality from pneumonia.6 CHF in COPD
patients may be an outcome of an overall systemic
inflammatory phenotype as recently suggested in the
literature and further research is required in this area.40
Dementia is increasingly prevalent in older adult patients
with CAP, since they share the common risk pattern of
nonlinear increase with age. Moreover, the use of sedative
medications and issues with swallowing may contribute to
impact of dementia in these patients.41 These factors may
apply to this cohort of COPD patients, which has a high
proportion of patients over age 65.
Epidemiology of pneumonia in COPD 1131Medications used to treat some co-morbid conditions,
such as peptic ulcer, may be significantly associated with
incidence of infection. This observed effect may be due to
current use of proton pump inhibitors (PPI) to treat peptic
ulcer rather than the condition itself. Gulmez et al.
reported increased risk of CAP in the general population
(OR 1.5 95% CI 1.3e1.7) among PPI users.42 The authors
stated that recent initiation of treatment with PPI’s (0e7
days prior to CAP episode), resulted in a strong association
with CAP (OR 5.0; CI 2.1e11.7). These findings warrant
further research into co-morbidity and concurrent medi-
cation risk in COPD patients who develop CAP.
Adjusted multivariate models did not report a significant
association between vaccine use and reduction in risk for
CAP. These results may be due to under-ascertainment of
vaccine uptake in the database due to (i) the vaccine
receipt not limited to GP’s office and may not be routinely
listed in personal prescribing variable listings or (ii) lower
uptake or provision of vaccine programmes in the 1990s.
Results from previous research on this topic have been
mixed. Lee and colleagues reported the risk of CAP hospi-
talization fell after vaccination from 8.0 (CI 4.4e14.5) to
3.9 (CI 2.6e5.9).43 However, Skull and colleagues reported
no benefit from use of either vaccine to prevent CAP in the
general population.44
Regarding respiratory medications, the results suggested
that ICS use was similar in both COPD patients with and
without pneumonia, but LABA was used more often by
patients with pneumonia. Confounding by severity, with
more severe COPD patients at higher risk of CAP being
prescribed LABA in addition to ICS, may explain these
results. Use of ICS, whilst restricted to an add-on therapy to
a long-acting bronchodilator in moderate to severe patients
in the guidelines,45 may be prescribed across all levels of
severity in general practice, particularly in those patients
with prior asthma diagnosis of which there were 45% in this
population. This use of ICS in COPD supports previous
findings of a UK study where CAP patients who were
admitted to the hospital from the community and were
users of ICS had diagnoses of chronic bronchitis and/or
asthma.33
In conclusion, our study indicated that, among COPD
patients treated in UK general practice, the incidence of CAP
was increased in sub-populations characterized by specific
risk factors, particularly older age, higher COPD severity,
prior CAP episodes, and some co-morbid conditions.Funding
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Community-Acquired Pneumonia significantly increases
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